Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125425 | 0.88 | ALDH1A1 (0.36) | MAPTSMN1; SMN2ACKR3KDM4EALDH1A1 | |
| SCHEMBL3647074 | 0.88 | GLS (0.34) | HTR2C | |
| SCHEMBL3807952 | 0.87 | MAPT (0.33) | MAPTSMN1; SMN2HTR2CACKR3KDM4E | |
| SCHEMBL3647079 | 0.87 | — | — | |
| SCHEMBL4131683 | 0.85 | EDNRA (0.40) | MAPTSMN1; SMN2 | |
| SCHEMBL4120348 | 0.83 | PPARG (0.35) | MAPTKDM4EALDH1A1 | |
| SCHEMBL4131864 | 0.82 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4126512 | 0.81 | KDM4E (0.38) | SMN1; SMN2HTR2CKDM4EALDH1A1 | |
| SCHEMBL3647076 | 0.79 | CTSA (0.31) | MAPTALDH1A1 | |
| SCHEMBL4129846 | 0.79 | ALDH1A1 (0.33) | MAPTACKR3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | MAPT 4258/4885SMN1; SMN2 4327/4885HTR2C 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.